Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment

Conclusions: ACQ and AQLQ are better markers than sputum eosinophilia in the evaluation of clinical improvement after 16 weeks of omalizumab treatment.

Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Hermanowicz-Salamon, J., Nejman-Gryz, P., Rubinsztajn, R., Paplinska-Goryca, M., Chazan, R. Tags: 5.3 Allergy and Immunology Source Type: research